CMS Lymphocyte Mitogen Response Assays Coverage Policy Update (NCD 257)

CMS has modified National Coverage Determination NCD 257, which governs Medicare coverage of lymphocyte mitogen response assays—a diagnostic lab test that measures immune response in peripheral blood lymphocytes. This update clarifies the boundaries between covered and non-covered uses, with specific implications for immunology, oncology, and rheumatology billing teams. If your practice orders or bills these assays, understanding the precise medical necessity criteria under this policy is essential before your next claim submission.

What Is a Lymphocyte Mitogen Response Assay Under CMS NCD 257?

The lymphocyte mitogen response assay is a diagnostic laboratory test that evaluates the functional capacity of a patient's immune system by measuring how peripheral blood lymphocytes respond to mitogenic stimulation. In clinical terms, it helps clinicians determine whether a patient's T cells or B cells are capable of mounting an adequate immune response.

This type of functional immune testing is distinct from simple lymphocyte counts or flow cytometry panels. It tells the clinician not just how many lymphocytes are present, but whether those lymphocytes are actually working—a critical distinction in patients with suspected or confirmed immunodeficiency.

Under the Centers for Medicare & Medicaid Services' benefit category structure, this test falls under Diagnostic Laboratory Tests, meaning standard lab billing rules apply, including medical necessity documentation requirements and diagnosis code alignment.

CMS Coverage Criteria: When the Test Is Medically Necessary

CMS covers the lymphocyte mitogen response assay under two specific circumstances:

1. Assessing lymphocytic function in diagnosed immunodeficiency diseases

The operative word here is "diagnosed." CMS does not cover this assay for screening purposes or to evaluate patients with a suspected but unconfirmed immunodeficiency. The documentation in the medical record must reflect an established diagnosis of an immunodeficiency disease—whether primary (congenital) or secondary (acquired)—before the test qualifies for coverage.

Examples of clinical contexts where this criterion would typically be met include patients with documented primary immunodeficiencies such as common variable immunodeficiency (CVID), patients with HIV/AIDS being evaluated for immune function beyond CD4 counts, or post-transplant patients with an established diagnosis of graft-mediated immune suppression.

2. Monitoring immunotherapy

The second covered indication is monitoring the effectiveness of immunotherapy. This applies when a patient is actively receiving immunotherapy for a covered condition and the clinician needs objective data to assess immune system response to that treatment. The key documentation requirement here is that the immunotherapy being monitored must be clearly tied to a covered indication—not cancer treatment monitoring, which falls into a separate, non-covered category.

What CMS Will Not Cover: The Cancer Treatment Monitoring Exclusion

This is where billing teams need to pay close attention. CMS explicitly excludes lymphocyte mitogen response assays when the purpose is monitoring the treatment of cancer, designating this use as experimental.

This exclusion has direct implications for oncology practices and any provider treating patients with malignancies who might otherwise consider ordering this assay to track immune response to chemotherapy, immunotherapy oncology agents, or other cancer-directed treatments.

The rationale from CMS is that using this assay for cancer treatment monitoring lacks sufficient evidence to be considered proven and non-experimental. From a billing standpoint, claims submitted with cancer-related diagnoses as the primary indication will be denied, and submitting them carries compliance risk.

If your oncology practice is ordering these assays for patients on immune checkpoint inhibitors or other cancer immunotherapy, the documentation must clearly distinguish between monitoring an underlying immunodeficiency diagnosis (potentially covered) versus monitoring the cancer treatment itself (not covered). That distinction is not always obvious in the chart—and it won't be obvious to a claims auditor either, so your documentation needs to make it explicit.

Affected Codes

The policy document for NCD 257 does not list specific CPT or HCPCS codes. CMS's NCD 257 does not enumerate procedure codes within the policy text itself.

What this means for your billing team: You will need to identify the applicable CPT codes for lymphocyte mitogen response assays through your lab's charge description master or by consulting your MAC's (Medicare Administrative Contractor's) local coverage policies, which may provide additional code-level guidance supplementing this NCD. Cross-referencing with your MAC is a necessary step before finalizing your billing approach under this policy.

Related ICD-10 Diagnosis Codes

No ICD-10 codes are enumerated in the NCD 257 policy document. However, your medical necessity documentation should reflect diagnosis codes consistent with diagnosed immunodeficiency diseases. Work with your clinical team to ensure the diagnosis codes on the claim align with the covered indications CMS has defined. Codes in the D80–D89 range (disorders involving the immune mechanism) are the most likely relevant family, but confirm with your MAC.

What Your Billing Team Should Do